Načítá se...
Biology and clinical application of CAR T Cells for B cell malignancies
Chimeric antigen receptor (CAR)-modified T cells have generated broad interest in oncology following a series of dramatic clinical successes in patients with chemorefractory B cell malignancies. CAR therapy now appears to be on the cusp of regulatory approval as a cell-based immunotherapy. We review...
Uloženo v:
| Vydáno v: | Int J Hematol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5512169/ https://ncbi.nlm.nih.gov/pubmed/27262700 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12185-016-2039-6 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|